Please login to the form below
mavacamten
This page shows the latest mavacamten news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Camzyos (mavacamten) for use across NHS England and Wales in adults with symptomatic
Latest news
-
BMS builds case for cardiovascular drug mavacamten with new analysis
BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia last year. ... BMS initially picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
-
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
BMS gained the rights to mavacamten as part of its acquisition of MyoKardia. ... BMS picked up mavacamten as part of its $13.1bn acquisition of MyoKardia, announced last year.
-
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
When compared to placebo, patients on mavacamten had greater reductions in post-exercise LVOT gradient as well as improved symptom scores. ... In addition to HCM, BMS is also set to explore the potential of mavacamten in additional indications, including
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
In the process, BMS will gain the rights to MyoKardia’s investigational treatment mavacamten, which is currently being developed as a treatment for obstructive hypertrophic cardiomyopathy (HCM), wherein the wall between
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
- Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens
No results were found
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
